EN
SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia
June 5, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.
BogotáBio, implementing an innovative collaboration model between the public and private sectors in the pharmaceutical sector in Bogota, aims to develop a range of vaccines that effectively address Colombia’s pressing need for immunization against various infectious diseases.
SINOVAC was selected by Bogota government as the winner among 15 biopharmaceutical companies invited globally through a tender process. The Company's extensive expertise and experience in vaccine R&D and production, and successful track record establishing vaccine manufacturing facilities will play a pivotal role in the new venture.
"BogotáBio will be one of the greatest innovations that we leave for Bogota in terms of research, development, and healthcare,” said Claudia López, mayor of Bogota, as she described the new facility’s impact during the 2023 Smart City Expo Bogotá.
"It is our honor to serve as the exclusive strategic partner of the Bogota government in the esteemed BogotáBio project. The widespread use of our COVID-19 vaccine demonstrates the trust placed in us, and we sincerely appreciate it," said Helen Yang, Chief Business Officer of SINOVAC. "We should all learn from the experience of this pandemic. The collaborative project between the Bogota government and SINOVAC aims to establish the country's self-sufficient capability in rapidly developing and producing vaccines, with the objective of preventing or mitigating the impact of future infectious threats.”
Colombia is one of the first countries in the world to adopt SINOVAC's COVID-19 vaccine, CoronaVac®, and granted emergency use approval for it in June 2021. To date, CoronaVac® and Healive®, SINOVAC’s hepatitis A vaccine, have been successfully distributed nationwide, effectively bridging the local vaccination gap with safe and affordable products.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.